PYX Resources: Achieving volume and diversification milestones. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Morning Bobbler - I had looked at Boehringer Ingelheim before but wrote them off as they're wholly privately owned so I presumed there would be no shares available to offer i.e. with a revenue of $9bn and no shares in circulation as such, how do we value circa 136000 shares in the company?
That all said, I'm puzzled by the following link - https://annualreport.boehringer-ingelheim.com/2023/letter/shareholder/index.html
If anyone can read or access it, good luck.
Regards.
Good morning Bobbler,
Excellent post and an important link.
It maybe worthwhile noting thst Acrivon has been designated fast track in endometrial and breast cancer ( 2023). Prexasertib and IV admistered chk1 2 inhibitor.
https://www.cancernetwork.com/view/fda-grants-ftd-to-prexasertib-in-ovarian-endometrial-cancers
Future is very bright for Chk1 inhibitors in combo therapy. On its own it is effective in what it us designed to do but needs assistance from DNA damaging agents eg gemcitabine.
Regards
Great research thank you. Am sure this company makes a asthma drug called spiriva as well . Thank you . Big German pharmaceutical....a beast you would say
Amazing research and a very big thank you. Add this drug (737) to 1801 and it goes some way to show Sareum have assets that can really make a difference to people’s lives. Let alone the company. Well done indeed.
HBD ref SRA737, I think the partner could possibly be Boehringer Ingelheim US subsidiary, technically this is a private US based company, ultimately owned by the parent in Germany. Boehringer Ingelheim Inc will have issued shares (private) and could therefore offer them as part of the deal.
Boehringer Ingelheim Collaborate extensively with Cancer Research Technology (trading as Cancer Research Horizons).
Full Disclosure of interactions with industry:
Sometimes, through Cancer Research Technology Limited, Cancer Research UK will receive shares rather than financial payments when research partnerships are created. Cancer Research UK does not usually apply a market value to such shareholdings but some information concerning these shareholdings can be found in Cancer Research Technology Limited’s statutory accounts filed at Companies House.
Boehringer are significantly involved in combo trials of xentuzumab with other drugs.
https://pubmed.ncbi.nlm.nih.gov/37308971/
Researchers based at the University of Oxford have discovered a way to boost the effectiveness of a new type of drug, called xentuzumab, which is currently being tested for breast cancer.
They found that xentuzumab was most effective when combined with drugs MK-8776 and SRA737, which block a protein called CHK1, and AZD1775 that blocks WEE1 protein.
https://breastcancernow.org/about-us/research-news/researchers-discover-way-boost-effectiveness-new-breast-cancer-drug/
Hi Lsesar - having completed P2 trials in combo, the BoD may have presumed 737 was at a point in its development that would attract larger upfront payments upon further licensing. Seems perfectly reasonable to me based on what I've read regarding deals for potentially P3-ready compounds. So who here expected a near carbon-copy of the Sierra deal?
Hbd - I think the reality was that the bod were reliant on a buoyant share price and fully intended to drawn down every penny of the RF funding - we all know how that panned out. I can’t see how they could think that 737 would provide enough funding. I think it is more naivety and poor management perhaps?
Conz/Dorset - at the time the BoD maybe knew a 737 license was in the closing stages and they probably thought there'd be an upfront payment large enough to cover our needs so RF was just a 'short-term payday loan' that turned out to be ill-advised and/or poorly chosen. Suddenly it went from we only need a a few quid to tide us over until the end of the month to oh crikey, we're now tied to a chair in a deserted warehouse and our kneecaps are soon to be history.
Luckily, enough shareholders heard the screaming and burst in to save the day.
I also think how can people so smart get it so wrong. It's not that this type of finance does not have form and past bad outcomes could have predicted the mess we ended up in especially with the jackals of AIM looking to feast on the wounded beast for short term gain. I recall the board making a specific point that its was flexible and only funds that were required would be drawn down which gives your theory legs. But then I think that people, no matter how smart need to have a business rather than a scientific brain/experience to navigate such treacherous waters and this lack of appointment was the root cause.
Just in my view
Anyone got views on the idea that a deal of some sort was considered so close that the RF finance was “just a financial gap filler” that went wrong? It’s all really messed with my head and investment!!
Volume would suggest another 200k sold today.
Me too. It must be close now…
Be glad when this overhang is exhausted and RF are out of the picture so that the SP can begin to rise again